Noile-Immune Biotech Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 28

Employees

  • Stock Symbol
  • 4893

Stock Symbol

  • Share Price
  • $0.48
  • (As of Wednesday Closing)

Noile-Immune Biotech General Information

Description

Noile-Immune Biotech Inc is engaged in the development of CAR-T cell therapy for solid cancers using its proprietary technology. The company's development pipeline and collaborative projects with other companies include different product candidates such as NIB102, NIB103, NIB104, ADAP01, AUTL01, etc. It operates in a single segment, the cancer immunotherapy drug discovery business.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 2-12-10 Shibadaimon 2-chome, Minato-ku
  • T&G Hamamatsucho Building 5F
  • Tokyo, 105-0012
  • Japan
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
TKS
Corporate Office
  • 2-12-10 Shibadaimon 2-chome, Minato-ku
  • T&G Hamamatsucho Building 5F
  • Tokyo, 105-0012
  • Japan

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Noile-Immune Biotech Stock Performance

As of 18-Nov-2026, Noile-Immune Biotech’s stock price is $0.48. Its current market cap is $20.9M with 43.4M shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.48 $0.51 $0.48 - $1.36 $20.9M 43.4M 219K -$0.11

Noile-Immune Biotech Financials Summary

As of 30-Jun-2026, Noile-Immune Biotech has a trailing 12-month revenue of $4.63K.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 9,238 10,515 15,289 24,872
Revenue 5 33 50 2,255
Net Income (4,882) (5,302) (6,368) (8,042)
Total Assets 22,632 25,645 30,568 40,977
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Noile-Immune Biotech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Noile-Immune Biotech‘s full profile, request access.

Request a free trial

Noile-Immune Biotech Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Noile-Immune Biotech‘s full profile, request access.

Request a free trial

Noile-Immune Biotech Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Noile-Immune Biotech Inc is engaged in the development of CAR-T cell therapy for solid cancers using its proprietary tec
Drug Discovery
Tokyo, Japan
28 As of 2025

Shanghai, China
 

Shanghai, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Noile-Immune Biotech Competitors (2)

One of Noile-Immune Biotech’s 2 competitors is Elpiscience Biopharmaceuticals, a Venture Capital-Backed company based in Shanghai, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Elpiscience Biopharmaceuticals Venture Capital-Backed Shanghai, China
Abbisko Medicine Formerly VC-backed Shanghai, China
You’re viewing 2 of 2 competitors. Get the full list »

Noile-Immune Biotech Patents

Noile-Immune Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026121219-A1 Method for producing genetically modified immunocompetent cells Pending 03-Dec-2024
EP-4382539-A1 Antibody binding to linker of scfv or like Inactive 02-Aug-2021
US-20240400718-A1 Antibody binding to linker of scfv or like Pending 02-Aug-2021
WO-2023013619-A1 Antibody binding to linker of scfv or like Inactive 02-Aug-2021
CA-3225682-A1 Anti-egfrviii antibody, polypeptide, cell capable of expressing said polypeptide, pharmaceutical composition comprising said cell, method for producing said cell, and polynucleotide or vector comprising nucleotide sequence encoding said polypeptid Pending 16-Jul-2021 A61K40/11
To view Noile-Immune Biotech’s complete patent history, request access »

Noile-Immune Biotech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Noile-Immune Biotech Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Noile-Immune Biotech‘s full profile, request access.

Request a free trial

Noile-Immune Biotech ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Noile-Immune Biotech’s complete esg history, request access »

Noile-Immune Biotech FAQs

  • When was Noile-Immune Biotech founded?

    Noile-Immune Biotech was founded in 2015.

  • Where is Noile-Immune Biotech headquartered?

    Noile-Immune Biotech is headquartered in Tokyo, Japan.

  • What is the size of Noile-Immune Biotech?

    Noile-Immune Biotech has 28 total employees.

  • What industry is Noile-Immune Biotech in?

    Noile-Immune Biotech’s primary industry is Drug Discovery.

  • Is Noile-Immune Biotech a private or public company?

    Noile-Immune Biotech is a Public company.

  • What is Noile-Immune Biotech’s stock symbol?

    The ticker symbol for Noile-Immune Biotech is 4893.

  • What is the current stock price of Noile-Immune Biotech?

    As of 18-Nov-2026 the stock price of Noile-Immune Biotech is $0.48.

  • What is the current market cap of Noile-Immune Biotech?

    The current market capitalization of Noile-Immune Biotech is $20.9M.

  • What is Noile-Immune Biotech’s current revenue?

    The trailing twelve month revenue for Noile-Immune Biotech is $4.63K.

  • Who are Noile-Immune Biotech’s competitors?

    Elpiscience Biopharmaceuticals and Abbisko Medicine are competitors of Noile-Immune Biotech.

  • What is Noile-Immune Biotech’s annual earnings per share (EPS)?

    Noile-Immune Biotech’s EPS for 12 months was -$0.11.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process